ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given. Keywo...
Main Authors: | Martin H.D. Neumann, Sebastian Bender, Thomas Krahn, Thomas Schlange |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037018300060 |
Similar Items
-
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
by: Minji Lim, et al.
Published: (2018-02-01) -
Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
by: Ângela Carvalho, et al.
Published: (2021-04-01) -
Liquid Biopsy, ctDNA Diagnosis through NGS
by: Chen Lin, et al.
Published: (2021-08-01) -
ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer
by: Laura Escudero, et al.
Published: (2021-04-01) -
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
by: Zhuo eZhang, et al.
Published: (2015-09-01)